These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
|Videos|August 31, 2020
What quality registry data reveal about urethral stricture treatment
Andrew J. Cohen, MD, discusses a recent study evaluating treatment of urethral stricture disease in the US.
Advertisement
Andrew J. Cohen, MD, assistant professor of urology at Johns Hopkins University, regarding a recently published study in Urology titled “Significant Management Variability of Urethral stricture Disease in United States: Data from the AUA Quality (AQUA) Registry.” Cohen says the study provides “a small glimpse into the truly enormous research potential of the AUA Quality Registry.”
Advertisement
Related to this article
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
Butterfly Medical has also submitted a premarket approval application to the FDA.
Advertisement
Advertisement
Trending on Urology Times
1
Urocross Expander System enters US commercial use for symptomatic BPH
2
Study assesses real-world outcomes with intranasal vardenafil for ED
3
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
4
Matching mCSPC treatment to the patient, not just the trial data
5